NewLink Genetics , Nasdaq: NLNK
Developing a Phase 3 drug for surgically-resected pancreatic cancer patients.
Industry: Health Care
First Day Return: +1.1%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 12/21/2010 |
| Offer Price | $7.00 |
| Price Range $10.00 - $12.00 | |
| Offer Shares (mm) | 6.2 |
| Deal Size ($mm) | $43 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 11/10/2011 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $43 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Ames, IA, United States |
| Founded | 1999 |
| Employees at IPO | 78 |
| Website www.linkp.com | |
NewLink Genetics (NLNK) Performance
